4basebio and Genezen Expand Synthetic DNA Collaboration
CAMBRIDGE, UK and INDIANAPOLIS, IN — August 26, 2026 4basebio PLC and Genezen announced an expanded, non-exclusive strategic collaboration...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, UK and INDIANAPOLIS, IN — August 26, 2026 4basebio PLC and Genezen announced an expanded, non-exclusive strategic collaboration...
Reykjavik, Iceland, August 21, 2026 Alvotech, a biotechnology company focused on the development and manufacture of biosimilar medicines, has...
Rancho Cordova, California, USA, August 21, 2026 SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced...
Philadelphia, August 20, 2026 iECURE announced that updated clinical data from the ongoing OTC-HOPE trial of ECUR-506 in infants...
AUSTIN, Texas, August 18, 2026 Genprex, Inc. has entered into a development and manufacturing agreement with a leading U.S.-based...
SAN FRANCISCO, Calif., June 26, 2026 Siren Biotechnology has been awarded an $8 million non-dilutive CLIN2 grant from the...
RANCHO CORDOVA, Calif., June 23, 2026 SK pharmteco has introduced SKyvec™, a next-generation multimodal viral vector platform designed to...
